RPRX Royalty Pharma plc
- Stocks
- Healthcare
- NASDAQ: RPRX
Price (delayed)
$37.32
Market cap
$20.98B
P/E Ratio
15.11
Dividend/share
$0.86
EPS
$2.47
Enterprise value
$27.51B
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals
Highlights
Royalty Pharma's EPS has increased by 38% YoY and by 29% QoQ
The net income has grown by 37% YoY and by 27% from the previous quarter
The company's quick ratio has shrunk by 88% YoY but it rose by 9% QoQ
The P/E is 69% lower than the 5-year quarterly average of 49.0 but 11% higher than the last 4 quarters average of 13.6
Royalty Pharma's debt has increased by 24% YoY
RPRX's equity is down by 5% since the previous quarter
Key stats
What are the main financial stats of RPRX
Market
Valuations
Earnings
Shares outstanding
562.24M
Market cap
$20.98B
Enterprise value
$27.51B
Price to earnings (P/E)
15.11
Price to book (P/B)
2.2
Price to sales (P/S)
7.18
EV/EBIT
20.55
EV/EBITDA
20.55
EV/Sales
12.15
Revenue
$2.26B
Gross profit
$2.26B
Operating income
$1.9B
Net income
$1.09B
EBIT
$1.34B
EBITDA
$1.34B
Free cash flow
$2.58B
Per share
Balance sheet
Liquidity
EPS
$2.47
EPS diluted
$2.46
Free cash flow per share
$5.91
Book value per share
$16.98
Revenue per share
$5.2
TBVPS
$40.43
Total assets
$17.61B
Total liabilities
$7.82B
Debt
$7.62B
Equity
$9.79B
Working capital
$660.39M
Debt to equity
0.78
Current ratio
1.56
Quick ratio
1.56
Net debt/EBITDA
4.88
Margins
Efficiency
Dividend
EBITDA margin
59.2%
Gross margin
100%
Net margin
48.3%
Operating margin
83.9%
Return on assets
6.1%
Return on equity
10.9%
Return on invested capital
5.7%
Return on capital employed
8.2%
Return on sales
59.2%
Dividend yield
2.3%
DPS
$0.86
Payout ratio
34.8%
RPRX stock price
How has the Royalty Pharma stock price performed over time
Intraday
0.54%
1 week
2%
1 month
3.58%
1 year
32.48%
YTD
46.3%
QTD
3.58%
Financial performance
How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.26B
Gross profit
$2.26B
Operating income
$1.9B
Net income
$1.09B
Gross margin
100%
Net margin
48.3%
The operating income has soared by 102% YoY and by 47% from the previous quarter
The operating margin has surged by 100% year-on-year and by 47% since the previous quarter
The net income has grown by 37% YoY and by 27% from the previous quarter
Royalty Pharma's net margin has increased by 35% YoY and by 27% QoQ
Price vs fundamentals
How does RPRX's price correlate with its fundamentals
Growth
What is Royalty Pharma's growth rate over time
Valuation
What is Royalty Pharma stock price valuation
P/E
15.11
P/B
2.2
P/S
7.18
EV/EBIT
20.55
EV/EBITDA
20.55
EV/Sales
12.15
The P/E is 69% lower than the 5-year quarterly average of 49.0 but 11% higher than the last 4 quarters average of 13.6
Royalty Pharma's EPS has increased by 38% YoY and by 29% QoQ
RPRX's P/B is 37% above its last 4 quarters average of 1.6 but 4.8% below its 5-year quarterly average of 2.3
RPRX's equity is down by 5% since the previous quarter
The P/S is 30% above the last 4 quarters average of 5.5 and 5% above the 5-year quarterly average of 6.8
Efficiency
How efficient is Royalty Pharma business performance
Royalty Pharma's return on sales has increased by 35% YoY and by 24% QoQ
RPRX's ROE is up by 35% YoY and by 28% from the previous quarter
The ROIC is up by 24% YoY and by 21% QoQ
The ROA has increased by 24% from the previous quarter and by 24% YoY
Dividends
What is RPRX's dividend history
DPS
$0.86
Dividend yield
2.3%
Payout ratio
34.8%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 125% more than its total liabilities
The company's quick ratio has shrunk by 88% YoY but it rose by 9% QoQ
The current ratio has dropped by 88% year-on-year but it has increased by 8% since the previous quarter
Royalty Pharma's debt is 22% lower than its equity
The debt to equity has increased by 26% YoY and by 5% QoQ
Royalty Pharma's debt has increased by 24% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.